

# NOF CORPORATION

LIFE SCIENCE DIVISION

YEBISU GARDEN PLACE TOWER

20-3, EBISU 4-CHOME, SHIBUYA-KU, TOKYO 150-6012 JAPAN

TEL.+81-3-5424-6741

FAX. +81-3-5424-5348



## NOF to Exhibit and Present Poster at SITC 2024 (Nov 8-9)

Tokyo, Japan – October 10, 2024 – NOF CORPORATION is pleased to announce its participation in the upcoming SITC 2024, which will be held at George R. Brown Convention Center, Houston, TX, U.S.A. from November 6 to 10.

The Conference website: <https://www.sitcancer.org/2024/home>

As a part of the event, NOF CORPORATION will showcase its products for Drug Delivery System at **Booth #712** from **November 8 to 9**.

In addition, Satoshi Kishida, Research Scientist at NOF CORPORATION, will give a poster presentation.

### **Title**

IL-2 mutein conjugated by cutting-edge PEG can improve the antitumor activity of CD8<sup>+</sup> T cells in the tumor microenvironment

### **Date & Time**

November 9 from 9:00 to 20:30, CST

### **Place**

Exhibit Halls AB-George R. Brown Convention Center, #948

### **Speaker**

Satoshi Kishida, *Research Scientist, NOF CORPORATION*

### **Abstract**

IL-2 can activate CD8<sup>+</sup> T cells and is well-known as a promising immunology agent. However, its therapeutic efficacy is limited due to its short half-life and IL-2 receptor alpha (IL-2Ra) capability. Moreover, the activation of CD8<sup>+</sup> T cells by IL-2 is suppressed in the tumor microenvironment (TME) due to the acidic condition. Therefore, long-acting IL-2, which reduces IL-2Ra capability and improves the antitumor activity of CD8<sup>+</sup> T cells in the TME, is desired to enhance the therapeutic efficacy of IL-2. Here, we developed IL-2 mutein, which has reduced IL-2Ra capability, and found that IL-2 mutein conjugated by cutting-edge PEG can improve antitumor activity of CD8<sup>+</sup> T cells in acidic conditions by in vitro assay, such as cell proliferation assay and cell killing assay, rather than IL-2 mutein conjugated by conventional PEG.

NOF CORPORATION invites attendees to visit booth #712 to explore their innovative drug delivery solutions and engage with their experts.

For further information or to arrange a meeting, please refer to the following contact information.

[Americas]

**NOF AMERICA CORPORATION**

E-mail [info@nofamerica.com](mailto:info@nofamerica.com)  
Tel +1-914-681-9790 (New York Office)  
+1-650-993-7375 (San Francisco Office)  
+1-914-704-7903 (Boston Office)

[Europe]

**NOF EUROPE GmbH**

E-mail [info-eu@nofeurope.com](mailto:info-eu@nofeurope.com)  
Tel +49-69-7706-100-0

[Asia Pacific, Japan]

**NOF CORPORATION**

Life Science Division

E-mail [ddsinfo@nof.co.jp](mailto:ddsinfo@nof.co.jp)  
Tel +81-3-5424-6741

[China]

**NOF (Shanghai) Co. Ltd.**

Tel +86-21-6210-1100